2020
The Moderate Alcohol and Cardiovascular Health Trial (MACH15): Design and methods for a randomized trial of moderate alcohol consumption and cardiometabolic risk
Spiegelman D, Lovato LC, Khudyakov P, Wilkens TL, Adebamowo CA, Adebamowo SN, Appel LJ, Beulens JW, Coughlin JW, Dragsted LO, Edenberg HJ, Eriksen JN, Estruch R, Grobbee DE, Gulayin PE, Irazola V, Krystal JH, Lazo M, Murray MM, Rimm EB, Schrieks IC, Williamson JD, Mukamal KJ. The Moderate Alcohol and Cardiovascular Health Trial (MACH15): Design and methods for a randomized trial of moderate alcohol consumption and cardiometabolic risk. European Journal Of Preventive Cardiology 2020, 27: 1967-1982. PMID: 32250171, PMCID: PMC7541556, DOI: 10.1177/2047487320912376.Peer-Reviewed Original ResearchConceptsModerate alcohol consumptionCardiovascular Health TrialAlcohol consumptionHealth trialsCardiovascular diseaseModerate alcoholNon-fatal ischemic strokeNon-fatal myocardial infarctionPrimary composite endpointCongestive heart failureCoronary heart diseaseModerate alcohol consumersAdults 50 yearsPublic health guidelinesAlcohol use disorderPreferred alcoholic beverageCardiometabolic effectsCardiometabolic riskCarotid revascularizationIschemic strokeSecondary outcomesComposite endpointHeart failurePrimary outcomeMyocardial infarction
2016
Probable Posttraumatic Stress Disorder in the US Veteran Population According to DSM-5: Results From the National Health and Resilience in Veterans Study.
Wisco BE, Marx BP, Miller MW, Wolf EJ, Mota NP, Krystal JH, Southwick SM, Pietrzak RH. Probable Posttraumatic Stress Disorder in the US Veteran Population According to DSM-5: Results From the National Health and Resilience in Veterans Study. The Journal Of Clinical Psychiatry 2016, 77: 1503-1510. PMID: 27631148, DOI: 10.4088/jcp.15m10188.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAfghan Campaign 2001-AgedCohort StudiesCombat DisordersComorbidityCross-Sectional StudiesDiagnostic and Statistical Manual of Mental DisordersFemaleFollow-Up StudiesHealth SurveysHumansIraq War, 2003-2011Life Change EventsMaleMental DisordersMiddle AgedResilience, PsychologicalStress Disorders, Post-TraumaticSurveys and QuestionnairesVeteransYoung AdultConceptsProbable posttraumatic stress disorderDSM-5 posttraumatic stress disorderPosttraumatic stress disorderUS veteran populationPsychiatric comorbidityUS veteransNational HealthVeteran populationVeterans StudyStress disorderPTSD symptomsOdds of moodHigh public health burdenPublic health burdenPopulation-based samplePast-month prevalenceDSM-5Specific PTSD symptomsHigh rateWeighted lifetimeNew symptomsHealth burdenLow prevalencePsychiatric disordersPTSD Checklist-5
2015
Early-Course Unmedicated Schizophrenia Patients Exhibit Elevated Prefrontal Connectivity Associated with Longitudinal Change
Anticevic A, Hu X, Xiao Y, Hu J, Li F, Bi F, Cole MW, Savic A, Yang GJ, Repovs G, Murray JD, Wang XJ, Huang X, Lui S, Krystal JH, Gong Q. Early-Course Unmedicated Schizophrenia Patients Exhibit Elevated Prefrontal Connectivity Associated with Longitudinal Change. Journal Of Neuroscience 2015, 35: 267-286. PMID: 25568120, PMCID: PMC4287147, DOI: 10.1523/jneurosci.2310-14.2015.Peer-Reviewed Original ResearchConceptsEarly course schizophreniaFunctional connectivityPrefrontal cortexImmediate symptom improvementSevere mental illnessEarly course patientsHealthy human subjectsHuman subjectsWhole-brain levelFunctional connectivity patternsResting-state fMRIIllness onsetSymptom improvementChronic illnessFunctional impairmentTherapeutic implicationsPFC connectivityOverall connection strengthMental illnessLongitudinal progressionLongitudinal changesSchizophrenia studiesSchizophreniaDiagnostic classificationPatients
2012
Glycine treatment of the risk syndrome for psychosis: Report of two pilot studies
Woods SW, Walsh BC, Hawkins KA, Miller TJ, Saksa JR, D'Souza DC, Pearlson GD, Javitt DC, McGlashan TH, Krystal JH. Glycine treatment of the risk syndrome for psychosis: Report of two pilot studies. European Neuropsychopharmacology 2012, 23: 931-940. PMID: 23089076, PMCID: PMC4028140, DOI: 10.1016/j.euroneuro.2012.09.008.Peer-Reviewed Original ResearchConceptsPilot studyRisk syndromeSyndrome patientsNegative symptomsShort-term pilot studyEffect sizeAdjunctive antipsychotic medicationOpen-label studyPatients meeting criteriaNMDA receptor functionDurability of effectPsychosis risk symptomsGlycine site agonistsGroup effect sizesWeeks of evaluationAntipsychotic medicationSyndrome subjectsPromising effect sizesTreatment needsLarge effect sizesMeeting criteriaCognitive impairmentReduced symptomsReceptor functionSymptoms
2011
Long-Acting Risperidone and Oral Antipsychotics in Unstable Schizophrenia
Rosenheck RA, Krystal JH, Lew R, Barnett PG, Fiore L, Valley D, Thwin SS, Vertrees JE, Liang MH. Long-Acting Risperidone and Oral Antipsychotics in Unstable Schizophrenia. New England Journal Of Medicine 2011, 364: 842-851. PMID: 21366475, DOI: 10.1056/nejmoa1005987.Peer-Reviewed Original ResearchConceptsInjectable risperidoneOral antipsychoticsQuality of lifeSchizoaffective disorderPsychiatrist's choiceSecond-generation antipsychotic agentsMore adverse eventsMore extrapyramidal symptomsPrimary end pointNeurologic side effectsExtrapyramidal adverse effectsRate of hospitalizationVeterans Affairs systemSocial Performance ScaleAdverse eventsExtrapyramidal symptomsOral treatmentAntipsychotic agentsUnstable diseasePsychiatric symptomsHigh riskHospitalizationSide effectsPatientsPsychiatric hospital
2009
Efficacy of D-Cycloserine for Enhancing Response to Cognitive-Behavior Therapy for Panic Disorder
Otto MW, Tolin DF, Simon NM, Pearlson GD, Basden S, Meunier SA, Hofmann SG, Eisenmenger K, Krystal JH, Pollack MH. Efficacy of D-Cycloserine for Enhancing Response to Cognitive-Behavior Therapy for Panic Disorder. Biological Psychiatry 2009, 67: 365-370. PMID: 19811776, DOI: 10.1016/j.biopsych.2009.07.036.Peer-Reviewed Original ResearchConceptsCognitive behavior therapyExposure-based cognitive behavior therapyD-cycloserinePanic disorderTherapeutic learningPanic Disorder Severity ScaleInternal sensationsManualized cognitive behavior therapyPlacebo-controlled augmentation trialD-cycloserine augmentationLarge effect sizesExposure interventionDCS administrationPill placeboAnxiety disordersDSM-IV criteriaSession 3Global ImpressionEffect sizePrimary outcome measureClinician Global ImpressionDisordersParticipantsLearningSignificant adverse effects
2006
Genetic and Environmental Predictors of Early Alcohol Use
Kaufman J, Yang BZ, Douglas-Palumberi H, Crouse-Artus M, Lipschitz D, Krystal JH, Gelernter J. Genetic and Environmental Predictors of Early Alcohol Use. Biological Psychiatry 2006, 61: 1228-1234. PMID: 17123474, DOI: 10.1016/j.biopsych.2006.06.039.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAlcohol DrinkingAllelesChildChild AbuseChild, PreschoolCohort StudiesDNAFemaleFollow-Up StudiesGenetic VariationGenotypeHumansMaleMental DisordersPredictive Value of TestsPrognosisPsychiatric Status Rating ScalesRiskSerotonin Plasma Membrane Transport ProteinsSocial EnvironmentSocial SupportStress Disorders, Post-TraumaticConceptsEarly alcohol useAlcohol useMaltreated childrenLater alcohol dependenceSubstance use disordersSubstance abuse problemsHigh riskMother-child relationsAlcohol dependenceSeverity of maltreatmentProtective factorsHome careIntervention effortsPotent predictorCommunity controlsAbuse problemsTransporter genotypeChildrenPredictorsMaltreatmentRisk
2005
Cortical γ-Aminobutyric Acid Concentrations in Depressed Patients Receiving Cognitive Behavioral Therapy
Sanacora G, Fenton LR, Fasula MK, Rothman DL, Levin Y, Krystal JH, Mason GF. Cortical γ-Aminobutyric Acid Concentrations in Depressed Patients Receiving Cognitive Behavioral Therapy. Biological Psychiatry 2005, 59: 284-286. PMID: 16139814, DOI: 10.1016/j.biopsych.2005.07.015.Peer-Reviewed Original ResearchMeSH KeywordsAdultCognitive Behavioral TherapyDepressive Disorder, MajorElectroconvulsive TherapyFemaleFollow-Up StudiesGamma-Aminobutyric AcidHumansImage Processing, Computer-AssistedMagnetic Resonance SpectroscopyMaleOccipital LobeOutcome and Process Assessment, Health CareSelective Serotonin Reuptake InhibitorsStatistics as TopicConceptsOccipital cortex GABA concentrationsSelective serotonin reuptake inhibitorsCognitive behavioral therapyElectroconvulsive therapyGABA concentrationDepressed patientsBehavioral therapyCortical GABA concentrationsEffects of CBTGamma-aminobutyric acid concentrationSerotonin reuptake inhibitorsΓ-aminobutyric acid (GABA) concentrationMajor depressive disorderProton magnetic resonance spectroscopyGABA contentAntidepressant actionSSRI treatmentCourse of CBTReuptake inhibitorsMedication treatmentDepressive disorderMajor depressionCerebrospinal fluidDepressed subjectsTherapy
2003
Increased Cortical GABA Concentrations in Depressed Patients Receiving ECT
Sanacora G, Mason GF, Rothman DL, Hyder F, Ciarcia JJ, Ostroff RB, Berman RM, Krystal JH. Increased Cortical GABA Concentrations in Depressed Patients Receiving ECT. American Journal Of Psychiatry 2003, 160: 577-579. PMID: 12611844, DOI: 10.1176/appi.ajp.160.3.577.Peer-Reviewed Original ResearchConceptsOccipital cortex GABA concentrationsCortical GABA concentrationsCourse of ECTGABA concentrationDepressed patientsConsiderable anticonvulsant effectsSevere refractory depressionGamma-aminobutyric acid concentrationProton magnetic resonance spectroscopyRefractory depressionAnticonvulsant effectsAntidepressant actionGABAergic transmissionECT treatmentGABAergic involvementEffective treatmentECT mechanismsDepressed subjectsPatientsSignificant increaseDepressionTreatmentECTMagnetic resonance spectroscopyAcid concentration
2002
Increased Occipital Cortex GABA Concentrations in Depressed Patients After Therapy With Selective Serotonin Reuptake Inhibitors
Sanacora G, Mason GF, Rothman DL, Krystal JH. Increased Occipital Cortex GABA Concentrations in Depressed Patients After Therapy With Selective Serotonin Reuptake Inhibitors. American Journal Of Psychiatry 2002, 159: 663-665. PMID: 11925309, DOI: 10.1176/appi.ajp.159.4.663.Peer-Reviewed Original ResearchConceptsOccipital cortex GABA concentrationsSelective serotonin reuptake inhibitorsSerotonin reuptake inhibitorsGamma-aminobutyric acidGABA concentrationReuptake inhibitorsDepressed patientsMajor depressionMedication-free depressed patientsMonths of treatmentInitiation of treatmentTreatment of depressionCSF of individualsProton magnetic resonance spectroscopyLow GABA concentrationsSSRI medicationAntidepressant actionSSRI treatmentOccipital cortexDepressed subjectsTreatmentDepressionPatientsSignificant increaseCommon mechanism
1993
Long-Term Outcome of Panic Disorder After Short-Term Imipramine and Behavioral Group Treatment
NAGY L, KRYSTAL J, CHARNEY D, MERIKANGAS K, WOODS S. Long-Term Outcome of Panic Disorder After Short-Term Imipramine and Behavioral Group Treatment. Journal Of Clinical Psychopharmacology 1993, 13: 16-24. PMID: 8098050, DOI: 10.1097/00004714-199302000-00003.Peer-Reviewed Original ResearchConceptsMonths of treatmentLong-term outcomesTime of admissionTime of dischargeEfficacy of treatmentPanic attack frequencyDSM-III diagnosesBehavioral treatment programBehavioral group treatmentNonpharmacological therapiesTerm outcomesMajor depressionAntipanic medicationSame doseLow doseLifetime diagnosisTreatment durationPatientsPanic disorderPanic attacksAttack frequencyImipramineTreatment programBehavioral therapyImpairment ratings
1992
Prolonged postictal encephalopathy in two patients with clozapine- induced seizures
Karper LP, Salloway SP, Seibyl JP, Krystal JH. Prolonged postictal encephalopathy in two patients with clozapine- induced seizures. Journal Of Neuropsychiatry 1992, 4: 454-457. PMID: 1422175, DOI: 10.1176/jnp.4.4.454.Peer-Reviewed Original Research
1989
Clinical and Medication Outcome After Short-term Alprazolam and Behavorial Group Treatment in Panic Disorder: 2.5-Year Naturalistic Follow-up Study
Nagy LM, Krystal JH, Woods SW, Charney DS. Clinical and Medication Outcome After Short-term Alprazolam and Behavorial Group Treatment in Panic Disorder: 2.5-Year Naturalistic Follow-up Study. JAMA Psychiatry 1989, 46: 993-999. PMID: 2818144, DOI: 10.1001/archpsyc.1989.01810110035005.Peer-Reviewed Original ResearchConceptsFU periodAlprazolam treatmentMajor depressionPanic disorderPanic attacksPanic attack frequencyBehavioral group treatment programGreater symptom severityAntipanic effectsNonpharmacologic therapiesMedication outcomesNaturalistic followGroup treatment programAlprazolam dosesSame doseLow doseLifetime diagnosisAttack frequencySymptom severityTreatment programBehavioral therapyPatientsAdmissionAlprazolamTreatment gains